Data from the International T-Cell Lymphoma Project [1] indicate that the 5-year overall survival (OS) rate was best for patients with anaplastic lymphoma kinase-positive (ALK +) anaplastic large-cell lymphoma (ALCL) (70%), followed by ALK-negative (ALK −) ALCL (49%) and other subtypes, such as PTCL, not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), and enteropathy-associated T-cell lymphoma, which were all < 40% [1]. The gene discussed is ALK; the disease is angioimmunoblastic T-cell lymphoma.